Contact
searchSearch
HMP Global
Login

Value-Based Care Topic Center

Featured

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
From Cancer Care Business Exchange
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Engaging Payers
How to Support the Adoption and Integration of Specialty Value-Based Care Models: A Conversation Across Multiple Stakeholders
02/09/2024
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses...
02/09/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes
01/25/2024
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters
01/24/2024
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
Expanding Access to Care Through Academic-Community Cancer Care Collaboration
01/23/2024
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials
12/28/2023
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
News
CPC & CBEx Keynote Session: How Do We Define Value-Based Oncology Care?
10/07/2023
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways

Expert Insights

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes
01/25/2024
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters
01/24/2024
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
Expanding Access to Care Through Academic-Community Cancer Care Collaboration
01/23/2024
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
Strategies the Health Care Industry Can Implement to Improve Black Women’s Participation in Clinical Trials
12/28/2023
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
Theresa Dreyer, MPH
Videos
Perspective on Lessons Learned from Academic Practices Participating in OCM
06/30/2023
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based...
06/30/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
Benefits and Challenges of the Enhancing Oncology Model
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
Focus on Outcomes: Quality Measurement Recommendations for CMS’ Medicaid Cell and Gene Therapy Access Model
06/08/2023
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
Davids Headshot
Interview
Integrating Real-World Evidence and Clinical Trial Data in CLL Management
01/17/2025
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S....
01/17/2025
Journal of Clinical Pathways
Romano Headshot
Interview
Personalizing Radiotherapy for Endometrial Cancer: Balancing Innovation and Quality of Life
01/17/2025
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D....
01/17/2025
Journal of Clinical Pathways
Ma Headshot
Interview
Advancing Biomarker Validation and Emerging Treatments in Metastatic Breast Cancer
01/16/2025
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X....
01/16/2025
Journal of Clinical Pathways
Bhat Headshot
Interview
Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic Leukemia
01/13/2025
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A....
01/13/2025
Journal of Clinical Pathways
Meisel Headshot
Interview
Improving Early Detection and Treatment for Breast Cancer Patients
01/10/2025
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L....
01/10/2025
Journal of Clinical Pathways
BDHC Thumbnail
Videos
Alternative Payment Models in Health Care: Successes, Failures, and What’s Next
01/09/2025
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health...
01/09/2025
Cancer Care Business Exchange
Patel Headshot
Interview
Evolving Clinical Pathways for Perioperative Strategies in Resectable NSCLC
01/09/2025
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel,...
01/09/2025
Journal of Clinical Pathways
Interview
Transforming Treatment Pathways for Endometrial Cancer
12/20/2024
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje...
12/20/2024
Journal of Clinical Pathways
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
Shaverdian Headshot
Interview
Incorporating Precision Medicine and AI Into NSCLC Radiation Approaches
12/19/2024
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek...
12/19/2024
Journal of Clinical Pathways

Newsfeed

News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
News
CPC & CBEx Keynote Session: How Do We Define Value-Based Oncology Care?
10/07/2023
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways
News
Regional Variations Detected in Clinical Trial Outcomes in Oncology
09/13/2022
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on...
09/13/2022
Journal of Clinical Pathways
News
Cancer Care Spending in the US May Not Be Proportionate With Better Cancer Outcomes
09/01/2022
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent...
09/01/2022
Journal of Clinical Pathways
News
Trends for Identifying Regulator and Payer Evidence Needs in Development of Oncology Drugs
08/26/2022
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of...
08/26/2022
Journal of Clinical Pathways
News
Labcorp Announces Spinoff of Clinical Development Business
08/26/2022
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
Projected Medicare Basic Part D Average Premium for 2023 Announced
08/26/2022
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
Examining Therapy Utilization and Quality of Care at Skilled Nursing Facilities Under Patient Driven Payment Model
08/16/2022
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
Defining the Notion of Value in Oncology Treatment
07/07/2022
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses...
07/07/2022
Journal of Clinical Pathways
News
Racial Disparities in Immune Checkpoint Inhibitor Treatment and Survival Among Patients With NSCLC
01/15/2025
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint...
01/15/2025
Journal of Clinical Pathways
News
Social Risks Lower Rates of Preventive Cancer Screenings
01/09/2025
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways
News
A Deep Learning Model for Predicting Immune Checkpoint Inhibitor Efficacy in NSCLC
01/08/2025
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and...
01/08/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
News
Travel and Financial Burdens Play a Role in Cancer Care
12/19/2024
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel...
12/19/2024
Journal of Clinical Pathways
News
An Evaluation of Endometrial Cancer Guidelines for Optimal Patient Care
12/17/2024
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers...
12/17/2024
Journal of Clinical Pathways
News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Exploring Lipid Metabolism Pathways in Endometrial Cancer Growth and Metastasis
12/17/2024
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as...
12/17/2024
Journal of Clinical Pathways
News
Study Highlights Risks and Outcomes of Radiation Therapy in Patients With Endometrial Cancer
12/13/2024
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer...
12/13/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Discussing Treatment Costs With Patients
03/12/2021
03/12/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
Nov-Dec 2024 Issue Cover

Current Issue

December 2024
Volume 10
Issue 6
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
News
ONCare Alliance Emerges as a Transformative Force in Independent Oncology and Cancer Care
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
Editor in chief Winston Wong, PharmD.
Editor Insights
Looking at 2023 Key Trends and Insights to Navigate the Future of Value-Based Care
02/13/2024
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use